Remaining balance of R&D Tax Incentive Rebate received
Filed with ASX · · 1 page · English
Story so far
Earlier from Acrux
- Appendix 4E and FY22 Annual Report
- Acruxs sixth generic dossier accepted by FDA for review
- Acrux announces commercial agreement with Padagis
- Successful patent litigation outcome
- Appendix 4D, Half Year Accounts as at 31 December 2021
Later from Acrux
- Chairman and CEO address to AGM
- Mutual Termination of Co-Development Agreement
- Launch of prilocaine and lidocaine cream in United States
- Gedeon Richter buyout Lenzetto Royalties for EUR4.1million
- Quarterly Activities / Appendix 4C Cashflow Report
Follow Acrux into a list and get an email when it puts out news.
Follow Acrux